M. Bravo

Lenalidomide plus Dexamethasone Has Similar Tolerability and Efficacy in Treatment of Relapsed/Refractory Multiple Myeloma Patients with or without History of Neuropathy.

M. Dimopoulos, M. Delforge, T. Facon, 2009 .

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

M. Dimopoulos, D. Siegel, J. Zeldis, 2011, Clinical lymphoma, myeloma & leukemia.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

J. Radford, L. Trümper, L. Arcaini, 2016, The Lancet. Oncology.

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

J. Radford, L. Arcaini, M. Trněný, 2014 .

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Michael L. Wang, I. Lossos, C. Reeder, 2017, Journal of Hematology & Oncology.

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael L. Wang, I. Lossos, C. Reeder, 2016 .

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

J. Radford, L. Trümper, L. Arcaini, 2016, The Lancet. Oncology.

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma versus therapy in

E. Campo, J. Radford, L. Arcaini, 2020 .